Phase II Clinical Trial for Recurrent Glioblastoma (rGBM) Cleared by Both US FDA and Taiwan FDA (TFDA), Set to Launch Across Leading Medical Centers in Taiwan and the United States!
VCRO marks another significant milestone in the global clinical development of cell therapy.
The Phase II clinical trial of Universal Allogeneic Chimeric Antigen Receptor T-cell (UCAR-T) therapy for recurrent glioblastoma (rGBM)—strategized and supported by VCRO’s specialized team—received IND clearance from the US FDA in December 2025 and the Taiwan FDA (TFDA) in August 2026. This dual clearance propels this innovative cell therapy product into a new phase of international clinical development.
Throughout this project, VCRO assisted the client with comprehensive clinical development strategy, protocol design, regulatory consultation, and IND submission planning. Leveraging robust strategic frameworks and the rigorous integration of scientific and regulatory data, the team successfully obtained regulatory authorization to proceed directly into Phase II clinical trials, significantly accelerating the asset’s development timeline.
The trial will be conducted across premier medical centers in both Taiwan and the United States. By bridging top-tier clinical research resources and multidisciplinary medical teams across both regions, the study aims to expedite the clinical validation of this novel UCAR-T therapy while establishing a solid foundation for future international development and global commercialization.
Deeply committed to cell therapy since 2008, VCRO possesses extensive experience in the clinical development of cell and regenerative medicine products, having successfully executed over 56 related projects to date. From early-stage development strategy, protocol design, regulatory filings, and agency interactions to multinational trial startup and execution, VCRO provides comprehensive, one-stop CRO solutions. Our deep domain expertise empowers sponsors to navigate complex regulatory and operational hurdles, accelerating their products toward the next pivotal milestone. If you are planning clinical development in Taiwan or the United States for cell therapies, regenerative medicine, advanced therapies, or other innovative drug candidates, visit the VCRO official website to contact our team and design the optimal clinical and regulatory roadmap for your pipeline.